RAS and bradykinin pathways in COVID-19 (WP4969)
Homo sapiens
This pathway describes imbalances in RAS and Bradykinin pathways in COVID-19. The expression of several genes in these pathways is affected in by SARS-CoV-2: * SERPING1 is downregulated, which cancels the suppression of F12 of the intrinsic coagulation cascade, resulting in the production of bradykinin from kallikrein and KNG. * ACE is downregulated, which increases bradykinin levels. * ACE2 is upregulated, ACE is downregulated, which causes an increase in Angiotensin 1-9 and sensitization of bradykinin receptors. * NFkappaB is suppressed by SARS-Cov-2, decreasing its binding to the ACE promoter and subsequent transcription. The result of a hyperactive bradykinin system is vasodilation to the point of vascular leakage and infiltration of inflammatory cells. The pathway is based on figure 2A from [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410499/ Garvin et al.]
Authors
Kristina Hanspers , Egon Willighagen , Friederike Ehrhart , Marvin Martens , Penny Nymark , Eric Weitz , and Denise SlenterActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
COVID-19Annotations
Pathway Ontology
disease pathwayDisease Ontology
COVID-19Cell Type Ontology
vascular associated smooth muscle cell| Label | Type | Compact URI | Comment |
|---|---|---|---|
| 20-HETE | Metabolite | chebi:34306 | |
| Vitamin D3 | Metabolite | chebi:28940 | |
| bradykinin, des-arg(9) | Metabolite | chebi:133068 | |
| L-arginine | Metabolite | chebi:16467 | |
| Aldosterone | Metabolite | cas:52-39-1 | |
| Bradykinin | Metabolite | hmdb:HMDB0004246 | |
| Angiotensin II | Metabolite | hmdb:HMDB0001035 | |
| Angiotensin I | Metabolite | pubchem.compound:3081372 | |
| Ang 1-7 | Metabolite | chemspider:110354 | |
| Ang 1-9 | Metabolite | kegg.compound:C15851 | |
| Arachidonic acid | Metabolite | chebi:15843 | |
| Ca++ | Metabolite | hmdb:HMDB0000464 | |
| Guanosine triphosphate | Metabolite | chebi:15996 | |
| nitric oxide | Metabolite | chebi:16480 | |
| Cyclic guanosine monophosphate | Metabolite | chebi:16356 | |
| Prostaglandin E2 | Metabolite | cas:363-24-6 | |
| Prostaglandin I2 | Metabolite | cas:35121-78-9 | |
| SERPINE1 | GeneProduct | ncbigene:5054 | SERPINE1 codes for plasminogen activator inhibitor-1 (PAI-1) |
| NFKB1 | GeneProduct | ensembl:ENSG00000109320 | |
| VDR | GeneProduct | ensembl:ENSG00000111424 | |
| MAPK1 | GeneProduct | ensembl:ENSG00000100030 | |
| SERPING1 | GeneProduct | ensembl:ENSG00000149131 | |
| CYP24A1 | GeneProduct | ensembl:ENSG00000019186 | |
| KLK1 | GeneProduct | ensembl:ENSG00000167748 | |
| F12 | GeneProduct | ensembl:ENSG00000131187 | |
| KLKB1 | GeneProduct | ensembl:ENSG00000164344 | |
| AGTR1 | GeneProduct | ncbigene:185 | |
| CPN1 | GeneProduct | ensembl:ENSG00000120054 | |
| AGTR2 | GeneProduct | ncbigene:186 | |
| BDKRB1 | GeneProduct | ncbigene:623 | |
| KNG1 | GeneProduct | ncbigene:3827 | |
| ACE | GeneProduct | ncbigene:1636 | |
| REN | GeneProduct | ncbigene:5972 | |
| ACE2 | GeneProduct | ncbigene:59272 | |
| AGT | GeneProduct | ncbigene:183 | |
| BDKRB2 | GeneProduct | ncbigene:624 | |
| CYP3A4 | GeneProduct | ensembl:ENSG00000160868 | |
| PRKG1 | GeneProduct | ensembl:ENSG00000185532 | |
| RHOA | GeneProduct | ensembl:ENSG00000067560 | |
| ROCK1 | GeneProduct | ensembl:ENSG00000067900 | |
| NOS1 | GeneProduct | ensembl:ENSG00000089250 | |
| NOS3 | GeneProduct | ensembl:ENSG00000164867 | |
| ACE2 | GeneProduct | ensembl:ENSG00000130234 | |
| TNF | GeneProduct | ensembl:ENSG00000232810 | |
| IL1A | GeneProduct | hgnc.symbol:IL1A | |
| NFKB1 | GeneProduct | hgnc.symbol:NFKB1 | |
| IL1B | GeneProduct | hgnc.symbol:IL1B | |
| Guanylate cyclase | Protein | uniprot:A0A140VJE6 |
References
- The control of protein phosphatase-1 by targetting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Alessi D, MacDougall LK, Sola MM, Ikebe M, Cohen P. Eur J Biochem. 1992 Dec 15;210(3):1023–35. PubMed Europe PMC Scholia
- Characterization of the receptor and the mechanisms underlying the inflammatory response induced by des-Arg9-BK in mouse pleurisy. Vianna RM, Calixto JB. Br J Pharmacol. 1998 Jan;123(2):281–91. PubMed Europe PMC Scholia
- Guanylate cyclase and the .NO/cGMP signaling pathway. Denninger JW, Marletta MA. Biochim Biophys Acta. 1999 May 5;1411(2–3):334–50. PubMed Europe PMC Scholia
- Pharmacogenetics of antihypertensive drug responses. Schwartz GL, Turner ST. Am J Pharmacogenomics. 2004;4(3):151–60. PubMed Europe PMC Scholia
- Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther. 2007 Sep;29(9):1803–24. PubMed Europe PMC Scholia
- Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Li P, Kondo T, Numaguchi Y, Kobayashi K, Aoki M, Inoue N, et al. Hypertension. 2008 Feb;51(2):252–8. PubMed Europe PMC Scholia
- Are we poised to target ACE2 for the next generation of antihypertensives? Ferreira AJ, Raizada MK. J Mol Med (Berl). 2008 Jun;86(6):685–90. PubMed Europe PMC Scholia
- Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Semin Thromb Hemost. 2020 Oct;46(7):835–7. PubMed Europe PMC Scholia
- COVID-19 and pneumonia: a role for the uPA/uPAR system. D’Alonzo D, De Fenza M, Pavone V. Drug Discov Today. 2020 Aug;25(8):1528–34. PubMed Europe PMC Scholia
- A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. Elife. 2020 Jul 7;9:e59177. PubMed Europe PMC Scholia
- The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Carvalho PR de, Sirois P, Fernandes PD. Peptides. 2021 Jan;135:170428. PubMed Europe PMC Scholia
- Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. Bernard I, Limonta D, Mahal LK, Hobman TC. Viruses. 2020 Dec 26;13(1):29. PubMed Europe PMC Scholia